Athenahealth’s Jonathan Bush staying put after past domestic violence is revealed

Athenahealth CEO Jonathan Bush issued an apology for “regrettable incidents” after it was reported he had admitted to assaulting his now former wife, but he’ll remain CEO of the health IT company as its under pressure to accept a takeover bid from activist hedge fund manager Paul Singer.

The Daily Mail obtained court documents from 2006 when Bush and his then-wife, Sarah Seldon, had fought over custody of their children. Seldon said there were “numerous physical altercations” including an incident where Bush was “repeatedly slamming his closed fist into her sternum.”

The documents added that Bush acknowledged “that such an incident took place.” In a statement, Bush said he takes “complete responsibility for all these regrettable incidents involving my dear former wife.”

“I have worked very hard since then to demonstrate my remorse, and today, Sarah and I have a strong, co-parenting relationship. I accept responsibility for my conduct and apologize to everyone involved,” Bush said.

In a separate statement, Seldon said “the incident did happen and is part of his and our family history; however, it should not define Jonathan as a person, or our relationship overall.”

According to Bloomberg, Athenahealth became aware of the allegations when contacted by the Daily Mail. It said in a statement that “we are fully committed to a safe and respectful work environment for all our employees.” Bush will continue to serve as CEO, the company said.

The report came as Athenahealth is fighting a takeover attempt by Singer’s firm Elliott Management. After taking a 9 percent stake in the company last year, the hedge fund made an offer of $160 per share—$7 billion overall—to buy it outright.

In its most recent statement, Athenahealth’s board of directors, led by former General Electric CEO Jeff Immelt, argued not all its shareholders support selling the company.

“The board will take into account the views of all of its shareholders as it evaluates the proposal from Elliott Management and considers the appropriate recommendation,” the company said. “The board will take the time necessary to complete its work so that it can recommend only those actions that it determines are in the best interests of all shareholders.”

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.